Best Telehealth Provider Networks for Health Brands

What should a health brand ask of a provider network?

Start with the proposed care program. Define the intended population, states, evaluation needs and follow-up model. Then ask whether the network can support that program through the appropriate clinicians and visit methods. A large roster or broad geographic statement is not enough to answer the question.

Clinical operations matter alongside staffing. Who handles scheduling, unanswered patient messages, additional information requests and escalation? Who maintains the clinical protocol? What happens when the patient is not eligible or needs a different level of care? The brand should understand these processes without trying to direct the individual medical decision.

Use the clinical-infrastructure guide and white-label telehealth guide to prepare a common brief. The shortlist below includes both integrated platforms and clinical infrastructure providers. The right comparison is the proposed service your business will receive, not a claim that all vendors sell the same thing.

How do coverage and operating models compare?

The table summarizes dated public positioning, with source links in the vendor sections below. Treat each geographic claim as the beginning of program verification. Missing detail is a question to resolve, not proof that a service is absent.

Why consider TEHR’s clinical infrastructure?

TEHR connects a brand to independent licensed clinical services with 50-state reach, alongside white-label technology, pharmacy coordination, AI-assisted intake, payments and subscriptions. Availability depends on the program, state, patient eligibility and clinical evaluation. TEHR does not practice medicine or prescribe.

Consider TEHR when your goal is a branded operating model rather than clinician access alone. The important evaluation is how the clinical handoff connects to the customer experience and commercial operation. Ask to see a routine evaluation and a case that requires additional information or a different next step.

The fee model is a flat platform subscription plus a flat transaction fee, with 0% revenue share. Contact TEHR for a scoped quote. Review the platform and pricing, and confirm the actual clinical-service costs and support scope. The trade-off is the same as any integrated purchase: the written proposal must match the responsibilities your team expects the provider to handle.

When should you evaluate OpenLoop?

OpenLoop’s platform page describes access to clinicians licensed across all 50 states, together with turnkey Launchpad and existing-stack integration routes. Its scope should not be reduced to clinician staffing alone.

Our assessment: OpenLoop is relevant when the buyer wants to compare an integrated launch model with a connection to infrastructure behind an existing product. Ask which clinical and administrative functions are included in the chosen route.

Obtain a program-specific statement of work and complete commercial schedule. The reviewed pages do not establish a universal public price or revenue-share policy, so neither should be invented. Read TEHR versus OpenLoop and, if switching, the migration guide. The service must fit the intended patient journey, not merely cover a map.

When should you evaluate Beluga Health?

Beluga’s homepage describes physician coverage across all 50 states and Washington, D.C., while its platform page presents several integration paths. Its pricing page states that it takes no cut of the brand’s customer revenue.

Our assessment: Beluga fits the shortlist when physician-led infrastructure and flexibility around a retained commerce stack are central requirements. Clarify the division between clinical backend responsibilities and the patient-facing systems your team or another partner will operate.

Compare the complete scoped costs, including platform, visits and relevant partner services. No revenue share is not unique to TEHR. The Beluga comparison helps frame the decision, and the migration guide covers the additional work when an existing operation is moving.

When should you evaluate Wheel?

Wheel’s network page describes an independent provider group with physicians and nurse practitioners, with additional specialties available, and advertises coverage across all 50 states, D.C. and Puerto Rico. Its launch page describes a configurable platform and care programs.

Our assessment: Wheel is relevant to buyers seeking an integrated clinical-operations model across a broader consumer or enterprise distribution strategy. Confirm the clinician types and visit methods available for the proposed program.

The reviewed pages do not establish a universal numerical pricing schedule or standard patient-migration process. Request those details directly rather than interpreting missing public information as an absent capability. Review TEHR versus Wheel and assess the complete service, including connected pharmacy and laboratory responsibilities where they apply.

When should you evaluate SteadyMD?

SteadyMD’s digital-health page describes a 50-state workforce including physicians, nurse practitioners and genetic counselors. Its API page distinguishes limited integration using the partner’s EMR from a more complete integration using SteadyMD’s system.

Our assessment: SteadyMD is worth considering when an existing product or clinical workflow is valuable and the buyer wants a configurable workforce and operating partner. Decide which system should hold clinical work and how information reaches the rest of the business.

A detailed fulfillment bundle, current B2B prices and standard migration terms were not established in the reviewed materials. Ask for the scope rather than assuming those services are included or unavailable. The SteadyMD comparison helps separate workforce procurement from a full consumer-brand operating package.

When should you evaluate MD Integrations?

MD Integrations’ homepage describes a physician-only network covering all 50 states, D.C. and Guam. Its FAQ describes API and ready-made options and explicitly states that it does not prescribe controlled substances.

Our assessment: it is relevant when physician-only staffing and the documented integration approach match the intended program. The controlled-substance exclusion is material; a broad hormone category should not be interpreted as evidence of testosterone prescribing.

Ask for current tailored pricing and a precise program scope. Also clarify record transfer, support and pharmacy responsibilities. Read TEHR versus MD Integrations before comparing proposals. The right network is determined partly by what your clinical program requires, so an explicit exclusion can be more useful than a vague claim to support everything.

When should you evaluate Qualiphy?

Qualiphy’s white-label page advertises licensed provider coverage in 48 states plus Washington, D.C., with synchronous and asynchronous workflows. Its pricing page lists $27.99 per completed consultation or exam without a signup or monthly subscription fee.

Our assessment: Qualiphy is relevant when a brand or healthcare office wants on-demand consult access and a usage-based starting point. Verify the exact states, encounter types and additional service costs for the intended offering.

Do not convert its published coverage into a 50-state claim. Its at-home testing page remains labeled coming soon. Review TEHR versus Qualiphy, and ask how commerce, ongoing care and migration responsibilities would be handled in the proposed arrangement.

When should you evaluate MyTelemedicine?

MyTelemedicine’s network page presents nationwide clinical access, while its platform page describes white-label technology and APIs. Its diagnostic-lab page describes test-request and results-review workflows.

Our assessment: it is worth evaluating for businesses adding branded clinical access to an existing service, including laboratory and pharmacy-related use cases. Ask for the exact state-by-program and clinician-type scope instead of equating a nationwide statement with universal availability.

Current platform prices, revenue-share terms and a detailed patient-migration service were not stated on the reviewed pages. Obtain a written proposal. The MyTelemedicine comparison helps a DTC buyer distinguish the documented clinical and technology model from assumptions about included commerce or outsourced fulfillment.

How should you verify network fit before contracting?

Ask for a program-specific coverage matrix, not only a roster size. HHS cross-state guidance explains why patient location and relevant authority matter. Verify the supported visit methods, clinical escalation process and staffing arrangement for the proposed service.

Then test the operating handoff. What happens if the patient needs additional information, cannot be treated or has a concern after the initial encounter? Who communicates the next step, and how does the brand’s support team know where to direct the question? Independent clinical judgment should remain clear throughout.

Use the cost guide to compare complete proposals and the migration checklist for existing patients. Selected TEHR peptide programs remain pending and are not open for prescribing or fulfillment. A network choice should be based on the current service you can responsibly operate, not an assumed future catalog.

What else should you know?